24 results about "Mycoplasma" patented technology

The invention relates to the technical field of biology, in particular to a primer probe combination product for respiratory tract infection detection. A plurality of specific primers and self-quenching probes are integrated in a single reaction system; simultaneous, rapid and rapid detection on 15 respiratory pathogens (including influenza A virus, influenza B virus, respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, mycoplasma pneumoniae, parainfluenza virus, rhinovirus, enterovirus, coronavirus, adenovirus, metapneumovirus, bordetella pertussis, bocavirus, chlamydia pneumoniae and chlamydia psittaci) is realized. The detection is accurate.

The invention provides a nano antibody specifically bound with mycoplasma pneumoniae P1 protein or an antigen binding fragment thereof, which can specifically recognize and bind the mycoplasma pneumoniae P1 protein and has better affinity with the mycoplasma pneumoniae P1 protein. The mycoplasma pneumoniae P1 protein can be used for preparing products for diagnosing, preventing and / or treating mycoplasma pneumoniae P1 protein infection or diseases caused by the mycoplasma pneumoniae P1 protein infection, or detecting the existence or the level of the mycoplasma pneumoniae P1 protein in a sample.

The invention discloses a reagent combination and a kit for detecting four respiratory tract pathogens based on qPCR, and belongs to the technical field of microbiological detection. Wherein the four respiratory tract pathogens are respectively human adenovirus, human bocavirus, bordetella pertussis and mycoplasma pneumoniae; the kit also comprises an optimized PCR (Polymerase Chain Reaction) buffer solution, DNA (Deoxyribose Nucleic Acid) polymerase and UDG enzyme. Through screening processes such as specific primer probe design, reagent formula and reaction system optimization, high sensitivity and high specificity are maintained while rapid detection is performed, and missing detection and misjudgment are effectively avoided.

The application discloses a kind of absolute quantitative detection method of child respiratory tract multi-pathogen based on multi-target ladder microarray and exogenous internal reference correction.The method sets up independent micro-reaction unit to different pathogen, adds fixed amount of exogenous internal reference nucleic acid, and calculates template number by positive unit proportion combined with Poisson distribution model, then corrects the result by using the theoretical addition amount of exogenous internal reference, so as to realize parallel detection and absolute quantification of pathogen such as bocavirus, adenovirus, mycobacterium tuberculosis and mycoplasma pneumoniae without standard curve and special digital PCR equipment.The application has the advantages of high sensitivity, strong anti-interference ability, suitable for mixed infection sample analysis and clinical application, etc.

This invention relates to a primer and probe composition and kit for detecting Mycoplasma pneumoniae and its drug resistance gene mutations. The primer and probe composition includes: a primer and probe set for detecting the wild type of Mycoplasma pneumoniae; a primer and probe set for detecting the A2063G mutation in Mycoplasma pneumoniae; a probe for detecting the A2064G mutation in Mycoplasma pneumoniae; a primer and probe set for detecting a human gene internal standard; and a competitive blocking agent. The primer and probe composition of this invention can detect Mycoplasma pneumoniae and its A2063G and A2064G drug resistance mutation sites with high sensitivity and specificity, solving the technical problems of false positives and insufficient specificity in existing quantitative real-time PCR for detecting single-base mutations in Mycoplasma pneumoniae.

The invention relates to the technical field of probiotic application, in particular to application of lactobacillus crispatus HC1261 in preparation of a microbial agent for improving female reproductive health and a composition for improving vagina inflammation. The lactobacillus crispatus HC1261 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on May 16, 2023, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No.27355; the microbial inoculum for improving female reproductive health can reduce the load of the ureaplasma urealyticum in the vagina. The lactobacillus crispatus HC1261 can be used for pertinently reducing the load of the ureaplasma urealyticum in the vagina, and can be used for reducing the related health risks of urethritis, cervicitis, pelvic inflammation, infertility and the like caused by the ureaplasma urealyticum.

The invention discloses a detection method for simultaneously determining multiple respiratory pathogens. According to the present invention, with the help of the recognized excellent signal amplification tool-CRISPR / Cas12a system and the DNA nanometer machine, the metal element labeling and the ICP-MS detection technology are assisted, such that the simultaneous detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the influenza A virus (H1N1) and the mycoplasma pneumoniae (MP) in the respiratory pathogens is completed so as to easily maintain the respiratory system safety of the whole human. When a compound formed by Cas12a / crRNA is specifically combined with a corresponding target DNA, the trans-shear activity of a CRISPR / Cas12a system can be activated, so that corresponding DNAzyme can be sheared, a DNA nano machine cannot run, lanthanide series metal elements on the DNA nano machine cannot be released, ICP-MS outputs a low signal, and quantitative analysis of multiple DNAs can be realized. The method for detecting the respiratory pathogens can realize simultaneous detection of multiple components, reduces the detection cost and the sample consumption, and has the advantages of high sensitivity and good specificity.

The invention relates to the technical field of biological detection, and discloses an oligonucleotide composition for detecting pathogens in a female lower genital tract, a kit and application. The oligonucleotide composition disclosed by the invention can be used for rapidly and simultaneously detecting a plurality of pathogens in gardnerella vaginalis, atriurella vaginalis, prevotella vulgaris, campylobacter mobilis, bacteroides, trichomonas vaginalis and mycoplasma in a sample in a high-specificity manner, and has high sensitivity and high stability; and a rapid, non-invasive, accurate and convenient detection method is provided for female reproductive health detection.

The application discloses a detection system of mycoplasma pneumoniae. According to the P1 gene of mycoplasma pneumoniae, RPA primers and crRNA required by a CRISPR system with LbCas12a as a core enzyme are designed and screened, an RPA system and a CRISPR system are established, the influence of each component of the CRISPR-LbCas12a system on the RPA system reaction and the influence of each component of the RPA system on each component of the CRISPR-LbCas12a system are tested, components are optimized according to the test results, and an RPA-LbCas12a integrated system capable of detecting a conserved fragment on the P1 gene of mycoplasma pneumoniae is established. The RPA-LbCas12a integrated system established in the application has high sensitivity, high detection efficiency, reduces nucleic acid pollution, and has a wide application prospect.

The invention discloses a Mycomonas rosae CCSM007 strain separated from human skin and capable of improving skin health and a metagen of the Mycomonas rosae CCSM007 strain, and belongs to the field of microbial technologies and medicines. The myxomonas rosae CCSM007 provided by the invention has a good barrier function repairing effect and application prospect in the aspect of external use, and the application prospect is specifically shown as follows: the activity of damaged HaCaT cells is improved in vitro, the expression of gene levels and protein levels in the aspects of functional proteins and structural proteins after damage is improved, and meanwhile, the expression of sphingomyelinase 1 (SMPD1) is improved. The metaplast of the myxomonas rosae has a huge application prospect in preparation of cosmetics or medicines for repairing skin barriers.

The invention belongs to the technical field of biology, and particularly relates to a microbial marker combination for evaluating the quality of polygonatum sibiricum and application, the microbial marker combination comprises one or more of Aspergillus, Cercophora, Escherichia. Shigilla, Mycoplasm, Muribacaceae, Pseudomonas, Colletotrichum and Asaia, a method and an evaluation model for evaluating the quality of polygonatum sibiricum are established by utilizing the microbial marker combination, the sensitivity is 100.0%, the specificity is 72.7%, the AUC is 89.8%, and the evaluation model is used for evaluating the quality of polygonatum sibiricum. The method has high accuracy, specificity and sensitivity, and the evaluation method is economical, practical and easy and convenient to operate and can be widely applied to quality evaluation of rhizoma polygonati.

The invention belongs to the technical field of biological detection, and particularly relates to a fluorescence-quenching labeled double-chain universal probe and a mediated amplification method and application thereof. The nucleic acid detection system comprises a fluorescence-quenching labeled double-stranded universal probe, the double-stranded universal probe is composed of two complementary oligonucleotide chains, and the nucleotide sequences of the double-stranded universal probe are shown as SEQ ID NO: 1-4. According to the pathogen nucleic acid detection method based on the universal probe and the target specific anchoring primer, a real-time quantitative PCR or isothermal amplification technology and a fluorescence resonance energy transfer mechanism are integrated, and synchronous and accurate detection of mycoplasma pneumoniae, streptococcus pneumoniae, haemophilus influenzae, influenza A virus, influenza B virus, novel coronavirus and the like is achieved. The method does not need pathogen culture, solves the problems of insufficient specificity, high cost, tedious operation and the like of a traditional detection technology, and can be applied to rapid diagnosis of clinical pathogen infection, reasonable use guidance of antibiotics and epidemiological monitoring.

The present invention pertains to a method for detecting microorganisms such as mycoplasma or mouse minute virus (MMV) in a sample, the method comprising: (i) performing PCR on a sample suspected of comprising mycoplasma DNA with a PCR reaction mixture comprising (1) a first primer (Pl) annealing to the reverse complement of a nucleic acid sequence of SEQ ID NO: 1 and a second primer (P2) annealing to a nucleic acid sequence of SEQ ID NO: 2, or (2) a third primer (P3) annealing to the reverse complement of a nucleic acid sequence of SEQ ID NO: 109 and a fourth primer (P4) annealing to a nucleic acid sequence of SEQ ID NO: 110; and (ii) detecting a PCR product, wherein the detection of a PCR product indicates that the sample comprises microroganisms, and the absence of a PCR product indicates that the sample does not comprise microroganisms. The present invention further pertains to a pair of primers for detecting mycoplasma or virus in a sample, and to a kit for detecting mycoplasma or virus in a sample.

The invention belongs to the field of biomedical treatment, and particularly relates to a convective amplification primer pair and probe for respiratory tract pathogenic bacteria and multiple detection application of the convective amplification primer pair and probe. The convection amplification primer pair comprises a legionella pneumophila primer pair, a mycoplasma pneumoniae primer pair and a bordetella pertussis primer pair, and the legionella pneumophila primer pair, the mycoplasma pneumoniae primer pair and the bordetella pertussis primer pair are respectively composed of an upstream primer and a downstream primer; each of the upstream primer and the downstream primer comprises a target nucleic acid complementary sequence and an interface sequence, and the interface sequence is located at the 5'end of the target nucleic acid complementary sequence and is not complementary with target nucleic acid; the target nucleic acid complementary sequence has a folded sequence, and the folded sequence is complementary with the interface sequence, so that the primer sequence has a curved hairpin structure, a probe is designed, and a respiratory tract pathogenic bacteria multiple detection kit is prepared. The multiple detection can avoid non-specific amplification and improve the detection sensitivity.

The application discloses a signal amplification composition for quadruple detection of respiratory pathogens, a detection kit thereof and application, and belongs to the technical field of biology. The signal amplification composition is composed of a fluorescently-labeled AuNS@MoS2-Probe and an amino-modified silica colloidal crystal SiO2 PC-NH2, and realizes double amplification of signals. For low-concentration clinical samples, the application can advance the Ct value, so that samples that need to be rechecked can be directly determined as positive, effectively solves the clinical problem that the signal of a low-concentration sample is weak and is easily submerged by background noise, and reduces the risk of missed detection. The kit is a freeze-dried preparation, has good normal-temperature stability, can simultaneously detect influenza virus A, influenza virus B, a novel coronavirus and mycoplasma pneumoniae, has the advantages of high sensitivity, strong specificity and low missed detection rate, and is suitable for clinical popularization and application.

This invention relates to the field of pathogen infection detection technology, specifically a method for visually tracking human bronchial organoids infected with Mycoplasma pneumoniae. It includes the following steps: (1) Constructing human bronchial organoids: culturing mature human bronchial organoids with cavities, the organoids comprising ciliated cells, basal cells, goblet cells, and Club cells, having a polarized three-dimensional structure with the apex facing outwards; (2) Mycoplasma pneumoniae culture and fluorescent labeling: Mycoplasma pneumoniae is amplified and cultured in MP complete medium, and then fluorescently labeled using CellTrace far-infrared cell staining solution; (3) Co-culture for infection: Mycoplasma pneumoniae fluorescently labeled in step (2) is co-cultured with the human bronchial organoids from step (1) for infection; (4) Live cell dynamic fluorescence tracking: Non-invasive in situ continuous imaging is performed on the human bronchial organoids infected by MP in step (3). This invention can achieve non-invasive dynamic tracking of the entire process of MP infection.

The present application relates to the technical field of microfluidics, and particularly relates to a kit for rapidly detecting 15 respiratory pathogens and a use method thereof.The kit comprises a plurality of reaction cavities, each of which has a primer group corresponding to 15 respiratory pathogens; the primer group comprises inner primers, outer primers and loop primers for PCR amplification of Mycoplasma pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Stenotrophomonas maltophilia, Haemophilus influenzae, Streptococcus pneumoniae, Escherichia coli, Legionella pneumophila, Burkholderia, Staphylococcus aureus, Corynebacterium striatum, Aspergillus, Pneumocystis jirovecii and Candida albicans.The present application can simultaneously detect 15 respiratory pathogens by adding samples once, avoids adding liquid reagents to multiple detection tubes, reduces the intensity of manual operation and the risk of mismatch.

The invention discloses a mycoplasma pneumoniae rapid quantitative detection kit based on nucleic acid extraction-free and application thereof, and belongs to the technical field of nucleic acid detection. The kit comprises a lysis solution, a detection premixed solution, a hydrogel monomer, a positive reference substance, a negative reference substance and a planar reaction chamber. The lysis system provided by the invention does not influence the activity of polymerase while ensuring effective lysis of pathogens, and realizes direct amplification from a clinical swab sample. By combining efficient LAMP amplification with a space-limited hydrogel microenvironment, absolute quantification is realized by fluorescent dot counting. The total detection time of the kit provided by the invention is shortened to be within 30 minutes, and the practicability of the kit in POCT and resource-limited regions is greatly improved.

This invention provides a subunit vaccine containing Mycoplasma pneumoniae HP14 / 30 fusion antigen and a mucosal adjuvant. The subunit vaccine comprises the Mycoplasma pneumoniae HP14 / 30 fusion antigen and a mucosal adjuvant in a mass ratio of 1-5:1. The HP14 / 30 fusion antigen is a recombinant protein co-expressed by chimeric fragments of the P1 and P30 proteins, with the amino acid sequence shown in SEQ ID NO:1. This vaccine is administered via mucosal routes such as nasal drops or oral inhalation. It efficiently induces respiratory mucosal-specific IgA and humoral IgG responses, significantly reduces pathogen load in the lungs, alleviates pathological damage to lung tissue, and does not induce enhanced respiratory disease (ERD). Its safety and protective efficacy are significantly superior to traditional inactivated vaccines and intramuscular vaccines. This invention fills the technological gap in human Mycoplasma pneumoniae subunit vaccines, is suitable for the prevention of Mycoplasma pneumoniae infection in children and adults, and has significant clinical application value.

The invention relates to the technical field of biological detection, in particular to a primer and probe combination for detecting five respiratory pathogens, a kit and application. The primer and probe combination comprises primers and probes for specifically detecting the following pathogens: novel coronavirus, influenza A virus, influenza B virus, respiratory syncytial virus and mycoplasma pneumoniae, and nucleotide sequences are shown as SEQ ID NO: 1-18. Based on the primer and probe combination of the multiple system, five targets can be simultaneously detected in one sample within 30 minutes. In addition, the sensitivity of the multiple systems is high, and the lowest detection limit is 200 copies / mL; and the kit has good specificity and has no cross reaction with other pathogens causing the same symptom. In addition, a PCR reagent comprising the primer and probe combination can be freeze-dried, a nucleic acid elution product to be detected is adopted to redissolve the PCR reagent during detection, and closed amplification is performed on a micro-fluidic chip.

The invention relates to a nucleic acid composition for mycoplasma pneumoniae detection, typing and / or drug resistance gene detection, a kit and application thereof. The nucleic acid composition and the kit not only can be used for efficiently, sensitively and accurately qualitatively / quantitatively detecting mycoplasma pneumoniae infection, but also can be used for synchronously determining the subtype and drug-resistant gene conditions of the infected mycoplasma pneumoniae, so that comprehensive and accurate mycoplasma pneumoniae infection related information is obtained; when the kit is applied to a clinical scene, the infection state, the typing result and the drug resistance condition of the mycoplasma pneumoniae can be efficiently and accurately obtained, and the kit has important value and significance for rapid detection and prevention and control of the mycoplasma pneumoniae, reasonable selection of antibiotics for treatment and clinical prognosis judgment.

The invention provides a human mycoplasma pneumoniae culture medium, a mycoplasma culture method and application, and relates to the technical field of microbial materials. The human mycoplasma pneumoniae culture medium comprises a basic culture medium, fetal calf serum, ampicillin sodium and an additive, and the additive comprises the following components based on the total volume of the human mycoplasma pneumoniae culture medium: 0.8-1.6 mg / L of glutamic acid, 0.4-1.2 mg / L of cysteine, 0.6-1.4 mg / L of glutathione, 50-150 mM / L of sodium pyruvate and 50-200 mL / L of a yeast extract. And the pH value of the human mycoplasma pneumoniae culture medium after sterilization is 7.6-8.0. According to the invention, the growth and reproduction speed of the mycoplasma pneumoniae is accelerated through the synergistic effect of the specific additive composition and content and the whole culture medium, a large number of mycoplasma pneumoniae wet thalli can be obtained in a short time, the survival rate of the human mycoplasma pneumoniae is obviously improved, and the method can be widely applied to large-scale production of the human mycoplasma pneumoniae natural antigen.

The invention discloses a traditional Chinese medicine preparation for treating throat discomfort caused by respiratory tract infection. The traditional Chinese medicine preparation is prepared from the following raw material medicines in parts by weight: 6-8 parts of cicada slough, 3-6 parts of liquorice, 10-15 parts of platycodon grandiflorum, 6-10 parts of rhizoma acori graminei, 6-10 parts of blackberry lily, 6 parts of stiff silkworm and 8-10 parts of radix scrophulariae. The traditional Chinese medicine preparation is used for treating throat discomfort (pharyngalgia, pharyngeal itching and the like) caused by respiratory tract infection (viruses, bacteria, mycoplasma and the like), including inflammation of the nasal cavity, the pharynx or the throat. The traditional Chinese medicine preparation can relieve symptoms such as pharyngalgia, red and swollen throat, hoarseness and cough and tonsil hyperemia caused by foreign matters in pharynx and pharynx itching which are caused by respiratory diseases, and can relieve the symptoms and reduce the recurrence rate in a short time.

This invention belongs to the biomedical field, specifically relating to a convective amplification primer set and probes for detecting multiple respiratory pathogens and their applications. The convective amplification primer set includes an upstream primer and a downstream primer. Both the upstream and downstream primers include a complementary sequence and a tailing sequence complementary to the target nucleic acid. The tailing sequence is located at the 5' end of the complementary sequence and is not complementary to the target nucleic acid. The complementary sequence contains a folded sequence, which is complementary to the tailing sequence, giving the primer sequence a curved hairpin structure. The target nucleic acid is a specific nucleotide sequence derived from influenza A virus, influenza B virus, and Mycoplasma pneumoniae. Primer probes were also designed, and a kit for detecting multiple respiratory pathogens was prepared. This kit can avoid non-specific amplification and improve detection sensitivity.